CellChorus Analysis: $3M Raised
What is CellChorus?
CellChorus develops TIMING™ technology to analyze immune cell behavior, enhancing understanding of cell interactions and performance for clinical applications.
Employees
4
Founded
2020
Revenue
$1.4M
Product Features & Capabilities
- TIMING™ platform, single-cell technology, evaluates cell movement, activation, interaction, killing, survival, time-lapse imaging microscopy, neural network detection, characterizes migration, contact dynamics, cell death, high-throughput microscopy experiments, artificial intelligence application,
How much CellChorus raised
Grant - $2,500,000
May 2, 2024Lead Investor: NCATS
Who are the founders of CellChorus
DM
Dan Meyer
CEO
NV
Navin Varadarajan
Founder
Investors
- National Institutes of Health (NIH)
- National Center for Advancing Translational Sciences (NCATS)
- Y Combinator
- NVIDIA Inception
- National Institute of General Medical Sciences
- Asymmetry Ventures
- Texas Halo Fund
Market Focus
CellChorus primarily focuses on the biotechnology industry, specifically in the field of immunology and single-cell analysis technologies for clinical applications.
Competitors Overview
CellChorus operates in the single-cell technology market, specifically focusing on immune cell evaluation through its TIMING™ platform. Its main competitors include:
- 10x Genomics: Known for its Gel Bead-in-Emulsions (GEM) technology, 10x Genomics offers high-throughput single-cell analysis p
See something that needs updating? Suggest edits to this profile.